Skip to main content
Journal ArticleOPEN ACCESS

Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer

  • Miles D
  • Roché H
  • et al.
The Oncologist (2011) 16(8) 1092-1100
DOI: 10.1634/theoncologist.2010-0307
221Citations
Citations of this article
178Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This double-blind, randomized, phase III clinical trial evaluated time to progression (TTP) and overall survival in women with metastatic breast cancer (MBC) who received sialyl-TN (STn) keyhole limpet hemocyanin (KLH) vaccine. Secondary endpoints included vaccine safety and immune response.

Cite

CITATION STYLE

APA

Miles, D., Roché, H., Martin, M., Perren, T. J., Cameron, D. A., … Ibrahim, N. K. (2011). Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer. The Oncologist, 16(8), 1092–1100. https://doi.org/10.1634/theoncologist.2010-0307

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free